BHV-7000 Acute Treatment of Bipolar Mania
A Phase 2/3, Multicenter, Inpatient, Placebo-Controlled, Double-blind Trial of BHV-7000 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
Sponsor: Biohaven Therapeutics Ltd.
Listed as NCT06419582, this PHASE2/PHASE3 trial focuses on Bipolar Disorder and remains completed. Sponsored by Biohaven Therapeutics Ltd., it has been updated 9 times since 2024, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE2/PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE2/PHASE3
▶ Show 4 earlier versions
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
First recorded
May 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biohaven Therapeutics Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .